• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

    2/14/24 4:36:10 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email
    SC 13G/A 1 d751841dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)

     

     

    ALLOGENE THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    019770 10 6

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 019770 10 6    13G    Page 2 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Arie Belldegrun, M.D.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States of America and Israel

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     3,192,581 Shares (1)

       6  

     Shared Voting Power

     

     6,703,323 Shares (2)

       7  

     Sole Dispositive Power

     

     3,192,581 Shares (1)

       8  

     Shared Dispositive Power

     

     6,703,323 Shares (2)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     9,895,903 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     5.8% (3)

    12  

     Type of Reporting Person

     

     IN

     

    (1)

    Includes 2,847,489 shares of common stock issuable within 60 days of December 31, 2023 upon the exercise of stock options held by the Reporting Person and 142,150 shares issuable upon the settlement of Restricted Stock Units held by the Reporting Person that are releasable within 60 days of December 31, 2023.

    (2)

    Includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 195,039 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun and (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, except to the extent of any pecuniary interest therein.

    (3)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 3 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Bellco Legacy IV, LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     4,710,120 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     4,710,120 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     4,710,120 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     2.8% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 4 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Bellco Legacy LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     195,039 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     195,039 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     195,039 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     0.1% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 5 of 9 Pages

     

     1   

     Names of Reporting Persons

     

     Vida Ventures LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Nevada

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0 Shares

       6  

     Shared Voting Power

     

     1,798,163 Shares

       7  

     Sole Dispositive Power

     

     0 Shares

       8  

     Shared Dispositive Power

     

     1,798,163 Shares

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,798,163 Shares

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row (9)

     

     1.1% (1)

    12  

     Type of Reporting Person

     

     OO

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.


    CUSIP No. 019770 10 6    13G    Page 6 of 9 Pages

     

    Item 1(a).

    Name of Issuer:

    Allogene Therapeutics, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    210 East Grand Avenue

    South San Francisco, CA 94080

     

    Item 2(a).

    Names of Persons Filing:

    Arie Belldegrun, M.D.

    Bellco Legacy IV LLC

    Bellco Legacy LLC

    Vida Ventures LLC

     

    Item 2(b).

    Address of Principal Business Office, or, if none, Residence:

    The address of Arie Belldegrun, M.D. is:

    10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067

    The address of Bellco Legacy IV LLC and Bellco Legacy LLC is:

    10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067

    The address of Vida Ventures LLC is:

    40 Broad Street, #201, Boston, MA 02109

     

    Item 2(c).

    Citizenship:

    Arie Belldegrun: USA and Israel

    Bellco Legacy IV LLC: Delaware

    Bellco Legacy LLC: Delaware

    Vida Ventures LLC: Nevada

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock

     

    Item 2(e).

    CUSIP No.:

    019770 10 6

     

    Item 3.

    Not Applicable.


    CUSIP No. 019770 10 6    13G    Page 7 of 9 Pages

     

    Item 4.

    Ownership

    The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover page to this Schedule 13G. Ownership is stated as of December 31, 2023. This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.

     

    Reporting Person

       Shares Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class(1)
     

    Arie Belldegrun

         3,192,581        3,192,581        6,703,323        3,192,581        6,703,323        9,895,903        5.8 % 

    Bellco Legacy IV, LLC

         4,710,120        0        4,710,120        0        4,710,120        4,710,120        2.8 % 

    Bellco Legacy LLC

         195,039        0        195,039        0        195,039        195,039        0.1 % 

    Vida Ventures LLC

         1,798,163        0        1,798,163        0        1,798,163        1,798,163        1.1 % 

     

    (1)

    This percentage is calculated based on 168,276,662 shares of common stock outstanding as of October 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 2, 2023.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable


    CUSIP No. 019770 10 6    13G    Page 8 of 9 Pages

     

    Item 10.

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    /s/ Arie Belldegrun
    Arie Belldegrun, M.D.

     

    Bellco Legacy IV LLC
    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Manager

     

    Bellco Legacy LLC
    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Manager

    Vida Ventures LLC

    By: VV Manager LLC, its Manager

    By:   /s/ Arie Belldegrun
    Name:   Arie Belldegrun, Senior Managing Director

     

    Get the next $ALLO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLO

    DatePrice TargetRatingAnalyst
    4/10/2026$6.00Buy
    Jefferies
    1/9/2026$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    10/10/2025Neutral → Underweight
    Analyst
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/14/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    8/8/2024$13.00 → $11.00Outperform
    Oppenheimer
    5/31/2024$11.00Overweight
    Piper Sandler
    1/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $ALLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Beneski Benjamin Machinas

    4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

    4/2/26 4:47:39 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Beneski Benjamin Machinas

    4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

    3/18/26 4:06:54 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chang David D

    4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

    3/18/26 4:05:48 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Belldegrun Arie was granted 344,828 shares and bought $4,999,997 worth of shares (1,724,137 units at $2.90) (SEC Form 4)

    4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

    5/20/24 9:33:32 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Parker Geoffrey M. bought $683 worth of shares (190 units at $3.60), increasing direct ownership by 0.02% to 819,590 units (SEC Form 4)

    4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

    3/6/24 9:52:06 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds from this offering are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions. In addition, Allogene has granted the underwriters for the offering a 30-day option to purchase up to 13,125,000 additional shares of its common stock at the pu

    4/14/26 9:50:00 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

    SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock. All of the shares are being offered by Allogene. In addition, Allogene intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $26.25 million of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Allogene expects to use the net proc

    4/13/26 4:01:00 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive pat

    4/13/26 8:00:00 AM ET
    $ALLO
    $NTRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    $ALLO
    SEC Filings

    View All

    SEC Form 424B5 filed by Allogene Therapeutics Inc.

    424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer)

    4/13/26 4:44:43 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Allogene Therapeutics Inc.

    8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

    4/13/26 4:09:04 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Allogene Therapeutics Inc.

    8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

    4/13/26 7:45:15 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Allogene with a new price target

    Jefferies resumed coverage of Allogene with a rating of Buy and set a new price target of $6.00

    4/10/26 12:25:15 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allogene upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    1/9/26 8:23:08 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allogene downgraded by Analyst

    Analyst downgraded Allogene from Neutral to Underweight

    10/10/25 8:22:32 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allogene Therapeutics Inc.

    SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

    11/12/24 1:26:25 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Allogene Therapeutics Inc.

    SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

    11/4/24 10:57:36 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

    SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

    2/14/24 4:36:10 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    Leadership Updates

    Live Leadership Updates

    View All

    Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

    SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

    10/22/24 4:05:00 PM ET
    $ALLO
    $ARTV
    $CDXS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.

    10/16/23 8:30:00 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allogene Therapeutics Appoints Earl Douglas as General Counsel

    SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company's legal function and serve as a member of the Leadership Team. "We are excited to welcome Earl who brings a tenure of experience guiding publicly-traded biotech companies on complex legal issues, corporate strategy and transactions," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "I also want to th

    8/14/23 8:30:00 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    Financials

    Live finance-specific insights

    View All

    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive pat

    4/13/26 8:00:00 AM ET
    $ALLO
    $NTRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

    41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7% Median Decrease in Plasma ctDNA at Day 45 Compared to a 26.6% Median Increase in the Observation ArmCema-Cel Treatment Well-Tolerated with Most Patients Managed Outpatient No Cases of CRS, ICANS, GvHD, or Treatment-Related Serious Adverse EventsNo Hospitalizations for Treatment-Related Adverse Events Community Cancer Centers, Including Sites New to CAR T Therapy, Accounted for Approximately 33% of Screening Activity and Cema-Cel Infusions  Enrollment Expected to Complete by Year-En

    4/13/26 7:30:00 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

    SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the Company will host a conference call and webcast to review the interim futility analysis from its pivotal, randomized Phase 2 ALPHA3 trial with cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation large B-cell lymphoma (LBCL) on Monday, April 13, 2026. The live conference call and webcast will take place at 5:30 a.m. PT / 8:30 a.m. ET. Please use this link to register. The webcast will be made available on

    4/10/26 4:02:00 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care